[go: up one dir, main page]

WO2014119985A3 - Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral - Google Patents

Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral Download PDF

Info

Publication number
WO2014119985A3
WO2014119985A3 PCT/MX2014/000028 MX2014000028W WO2014119985A3 WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3 MX 2014000028 W MX2014000028 W MX 2014000028W WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3
Authority
WO
WIPO (PCT)
Prior art keywords
selective phosphodiesterase
phosphodiesterase enzyme
enzyme inhibitor
pharmaceutical composition
gel form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2014/000028
Other languages
English (en)
Spanish (es)
Other versions
WO2014119985A2 (fr
Inventor
Miguel Ángel GARCIA PÉREZ
Gabriel MARCELÍN JIMÉNEZ
Concepción Albina VÁZQUEZ FLORES
Ricardo David ÁVILA CEDILLO
Alionka Citlalli P. ANGELES MORENO
Octavio CARO RODRÍGUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014119985A2 publication Critical patent/WO2014119985A2/fr
Publication of WO2014119985A3 publication Critical patent/WO2014119985A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une nouvelle composition semi-solide stable pour l'administration orale qui comprend au moins un agent inhibiteur sélectif de l'enzyme phosphodiestérase et/ou au moins un excipient pharmaceutiquement acceptable. La composition, une fois administrée par voie orale, conserve une libération soutenue, dupliquant le temps de permanence de l'ingrédient actif dans l'organisme et prolongeant l'effet thérapeutique de l'inhibiteur sélectif de l'enzyme phosphodiestérase. La composition semi-solide est destinée à être utilisée pour l'inhibition sélective de l'enzyme phosphodiestérase par exemple de manière non limitative, pour le contrôle ou le traitement de la dysfonction érectile, présentant un effet thérapeutique pouvant aller jusqu'à 8 heures.
PCT/MX2014/000028 2013-01-31 2014-01-28 Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral Ceased WO2014119985A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2013001279A MX2013001279A (es) 2013-01-31 2013-01-31 Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MXMX/A/2013/001279 2013-01-31

Publications (2)

Publication Number Publication Date
WO2014119985A2 WO2014119985A2 (fr) 2014-08-07
WO2014119985A3 true WO2014119985A3 (fr) 2014-11-27

Family

ID=49552933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000028 Ceased WO2014119985A2 (fr) 2013-01-31 2014-01-28 Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral

Country Status (2)

Country Link
MX (1) MX2013001279A (fr)
WO (1) WO2014119985A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584248B1 (es) * 2015-03-24 2017-04-19 Farmalider, S.A. Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN112587476B (zh) * 2020-12-23 2022-09-27 无锡市妇幼保健院 一种适用于新生儿动脉高压的西地那非啫喱新剂型及其制备方法
CN113577079B (zh) * 2021-07-28 2022-08-23 山东裕欣药业有限公司 一种磷酸二酯酶抑制剂的制备方法及组合物
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060353A1 (fr) * 2000-02-21 2001-08-23 Fujisawa Pharmaceutical Co., Ltd. Preparation liquide a absorbabilite amelioree
JP2010241798A (ja) * 2009-03-18 2010-10-28 Daiichi Sankyo Healthcare Co Ltd シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器
DE102009033396A1 (de) * 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
CN102204917A (zh) * 2011-03-30 2011-10-05 天津红日药业股份有限公司 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060353A1 (fr) * 2000-02-21 2001-08-23 Fujisawa Pharmaceutical Co., Ltd. Preparation liquide a absorbabilite amelioree
JP2010241798A (ja) * 2009-03-18 2010-10-28 Daiichi Sankyo Healthcare Co Ltd シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器
DE102009033396A1 (de) * 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
CN102204917A (zh) * 2011-03-30 2011-10-05 天津红日药业股份有限公司 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200171, Derwent World Patents Index; AN 2001-616113 *
DATABASE WPI Week 201076, Derwent World Patents Index; AN 2010-N63986 *
DATABASE WPI Week 201105, Derwent World Patents Index; AN 2011-N80718 *
DATABASE WPI Week 201113, Derwent World Patents Index; AN 2011-A90507, DW *

Also Published As

Publication number Publication date
MX2013001279A (es) 2013-08-26
WO2014119985A2 (fr) 2014-08-07

Similar Documents

Publication Publication Date Title
MX2022006258A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
WO2014119985A3 (fr) Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2014027975A3 (fr) Nouvelles formulations pharmaceutiques administrées par voie orale
NZ778223A (en) Modified release tablet formulations containing phosphodiesterase inhibitors
TN2015000135A1 (en) Modified release formulations for oprozomib
HK1217495A1 (zh) 治疗活性的作为17β-羟基类固醇脱氢酶抑制剂的17-氮取代雌三烯噻唑衍生物
WO2014130691A3 (fr) Formulations pharmaceutiques de nitrite et leurs utilisations
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2022013450A (es) Formulaciones farmaceuticas.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
WO2015166418A3 (fr) Composition pharmaceutique pour le traitement allopathique de la douleur, au moyen d'un agent actif au kétorolac trométhamine et au chlorhydrate de tramadol
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
WO2019203759A3 (fr) Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
EA201200799A1 (ru) Гепатопротекторное средство
MX388249B (es) Composición farmacéutica de desloratadina para ser administrada por vía oral, para el tratamiento de enfermedades relacionadas con la histamina.
MX352778B (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14745757

Country of ref document: EP

Kind code of ref document: A2